scispace - formally typeset
M

Maria Bota

Researcher at University of Strathclyde

Publications -  13
Citations -  823

Maria Bota is an academic researcher from University of Strathclyde. The author has contributed to research in topics: Prostate cancer & Breast cancer. The author has an hindex of 7, co-authored 13 publications receiving 658 citations.

Papers
More filters
Journal ArticleDOI

Diabetes and breast cancer risk: a meta-analysis

TL;DR: The risk of breast cancer in women with type 2 diabetes is increased by 27%, a figure that decreased to 16% after adjustment for BMI, and no increased risk was seen for women at pre-menopausal ages or with type 1 diabetes.
Journal ArticleDOI

DataSHIELD: taking the analysis to the data, not the data to the analysis

TL;DR: The technical implementation of DataSHIELD is described, using a modified R statistical environment linked to an Opal database deployed behind the computer firewall of each DC, which is currently used by the Healthy Obese Project and the Environmental Core Project for the federated analysis of 10 data sets across eight European countries.
Journal ArticleDOI

Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database

TL;DR: Over the past 40 years, there has been considerable disparity in the level of colorectal cancer mortality between European countries, as well as between men and women and age categories.
Journal ArticleDOI

Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis

TL;DR: To review and quantify the association between endogenous and exogenous testosterone and prostate‐specific antigen (PSA) and prostate cancer, a large number of patients with known or suspected cases of prostate cancer were diagnosed with at least some types of cancer.
Journal ArticleDOI

Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies

TL;DR: The recent prescription of incretin therapy is associated with an increased risk of pancreatic cancer, and the reason for such an increase is likely the consequence of an occult pancreaticcancer that provokes or aggravates diabetes.